Compare EXPI & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXPI | PRCT |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | N/A | 2021 |
| Metric | EXPI | PRCT |
|---|---|---|
| Price | $10.58 | $36.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $12.00 | ★ $51.50 |
| AVG Volume (30 Days) | 1.4M | ★ 1.6M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,678,653,000.00 | $299,907,000.00 |
| Revenue This Year | $6.03 | $48.34 |
| Revenue Next Year | $5.37 | $29.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 5.12 | ★ 50.07 |
| 52 Week Low | $6.90 | $27.80 |
| 52 Week High | $13.35 | $92.92 |
| Indicator | EXPI | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 62.12 |
| Support Level | $10.16 | $33.27 |
| Resistance Level | $10.71 | $38.11 |
| Average True Range (ATR) | 0.38 | 1.83 |
| MACD | -0.08 | 0.72 |
| Stochastic Oscillator | 22.06 | 80.10 |
eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services. The company mainly operates in the United States and Canada, and it also has operations in the United Kingdom, Australia, South Africa, France, India, Portugal, and Mexico, among others.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.